Cue biopharma reports qtrly loss per share of $0.48

Cue biopharma reports first quarter 2020 results, updates of cue-101 phase 1 dose escalation study and recent business highlights.cue biopharma inc- qtrly loss per share $0.48.
CUE Ratings Summary
CUE Quant Ranking